...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer.
【24h】

The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer.

机译：BRCA1 / BRCA2 / Rad51复合物是早期乳腺癌的预后和预测因素。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND PURPOSE: The breast cancer susceptibility genes BRCA1 and BRCA2 interact with Rad51, one of the central components in the homologous recombination repair pathway. This study evaluates the prognostic and predictive role of BRCA1, BRCA2 and Rad51, individually and as a complex, in breast cancer. MATERIALS AND METHODS: Expression of BRCA1, BRCA2 and Rad51 was investigated using immunohistochemistry in tumours from 224 women with early breast cancer, who were randomised to receive postoperative radiotherapy or adjuvant chemotherapy (CMF). RESULTS: Fifty-three percent (112/212) of the tumours had reduced expression of the BRCA1/BRCA2/Rad51 complex. Low expression correlated to high histologic grade (p=0.05). Patients with low expression of the complex developed significantly more local recurrences as compared to patients with high expression (RR=3.20, 95% CI 1.48-6.88, p=0.003). Expression of the BRCA1/BRCA2/Rad51 complex was an independent prognostic factor in multivariate analysis (p=0.03).Patients with low expression of the complex responded well to radiotherapy (RR=0.31, 95% CI 0.14-0.70, p=0.005), whereas patients with high expression had few local recurrences and no additional benefit from radiotherapy (RR=1.08, 95% CI 0.40-2.90, p=0.88). CONCLUSIONS: Low expression of the BRCA1/BRCA2/Rad51 complex is a marker of poor prognosis, but predicts good response to radiotherapy in patients with early breast cancer.
机译：背景与目的：乳腺癌易感性基因BRCA1和BRCA2与Rad51相互作用，Rad51是同源重组修复途径中的重要组成部分。这项研究评估了BRCA1，BRCA2和Rad51在乳腺癌中的预后和预测作用。材料与方法：采用免疫组织化学方法对224例早期乳腺癌妇女的肿瘤进行了BRCA1，BRCA2和Rad51的表达研究，这些妇女被随机分配接受术后放疗或辅助化疗（CMF）。结果：53％（112/212）的肿瘤的BRCA1 / BRCA2 / Rad51复合物表达降低。低表达与高组织学分级相关（p = 0.05）。与高表达患者相比，低表达复合物的患者发生局部复发的概率更高（RR = 3.20，95％CI 1.48-6.88，p = 0.003）。在多变量分析中，BRCA1 / BRCA2 / Rad51复合物的表达是一个独立的预后因素（p = 0.03），低表达复合物的患者对放疗反应良好（RR = 0.31，95％CI 0.14-0.70，p = 0.005） ，而高表达患者几乎没有局部复发，也没有从放疗中获益（RR = 1.08，95％CI 0.40-2.90，p = 0.88）。结论：BRCA1 / BRCA2 / Rad51复合物的低表达是预后不良的标志，但预示着早期乳腺癌患者对放疗的良好反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号